Liu S, et al. IMPOWER 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. IASLC 2018, abstract PL02.07.
Veel nieuwe behandelopties verwacht bij behandeling urotheelcelcarcinoom
nov 2019 | Immuuntherapie, Uro-oncologie